Delpharm, a CDMO, has expanded its pharmaceutical network with the acquisition of Astellas’ Meppel pharmaceutical manufacturing facility in the Netherlands.
Astellas Pharma is selling its manufacturing plant in Meppel, the Netherlands, to contract manufacturer Delpharm.
Japanese drugmaker Astellas Pharma sold off its Netherlands manufacturing facility to French CDMO Delpharm Industries for an undisclosed price.
Delpharm, a CDMO, has expanded its pharmaceutical development services with the acquisition of the Leiden Development Center from Dr Reddy's in the Netherlands. This center employs forty highly qualified personnel and is located in a 3,500 square meter unit equipped with state-of-the-art technologies to develop injectable formulation for small and large molecules and to manufacture small batches for clinical trials.
The pharmaceutical company Delpharm has appointed Alain Kirchmeyer to the position of managing director.
Delpharm is investing € 28 million on a sterile line to manufacture prefilled syringes at its plant in Tours, France.
First, the company has reached a deal to sell its Ringaskiddy campus near Cork, Ireland, to contract manufacturer Sterling Pharma Solutions. Separately, CDMO compatriot Delpharm has completed its acquisition of a Quebecois manufacturing plant from Novartis’ generics unit, Sandoz.
EU blesses Catalent, Delpharm sites to produce mRNA COVID shots
With plans to take its consumer healthcare joint venture with Pfizer public in the next few years, GlaxoSmithKline has been in Marie Kondo mode for some of its expansive global assets. After cutting a Canadian plant with 400 workers earlier this year, GSK is now hiving off an even bigger facility in Poland.
GlaxoSmithKline has sold off its Pozna?, Poland, manufacturing site and 700 workers to CDMO Delpharm as part of a global asset pare-down.